| 08:00-08:25 | 专题报告 |
儿童法布雷病的高危筛查及基因治疗 |
|
||||
| 08:25-08:50 | 专题报告 |
表观遗传调控肾小管细胞衰老的作用与机制 |
|
||||
| 08:50-09:15 | 专题报告 |
儿童罕见病临床试验的实践与优化 |
|
||||
| 09:15-09:40 | 专题报告 |
走出VUS困境:儿科罕见肾脏病错义突变的干试验评估与临床决策 |
|
||||
| 09:40-10:05 | 专题报告 |
遗传性肾小球基底膜病诊疗进展 |
|
||||
| 10:05-10:15 |
集体答疑、讨论 |
||||||
| 10:25-10:31 | 大会发言 |
Founder mutations and therapeutic thresholds in COQ8B Nephropathy: A large multicenter study from China based on the CCGKDD registry |
|
||||
| 10:31-10:37 | 大会发言 |
基于临床队列与单细胞转录组的儿童IgA血管炎肾炎肾脏免疫微环境及炎症机制研究 |
|
||||
| 10:37-10:43 | 大会发言 |
GCLM K34乳酸化修饰调控肾小管上皮细胞铁死亡促进ADPKD进展的机制研究 |
|
||||
| 10:43-10:49 | 大会发言 |
Dent病发病新机制及药物筛选 |
|
||||
| 10:49-10:55 | 大会发言 |
Mixed exposure to urinary phthalate metabolites and age - across decline in renal function: Complex sampling analysis in NHANES, comparison of urine dilution, and mechanistic clues |
|
||||
| 10:55-11:01 | 大会发言 |
微囊化儿茶素对大鼠5/6肾切除残余肾功能肾病理肾血管的修复研究 |
|
||||
| 11:01-11:07 | 大会发言 |
ANGPTL3 Drives Proteinuria and Dyslipidemia in Proteinuric Kidney Disease: Therapeutic Targeting with a Novel Nanobody Fusion Protein |
|
||||
| 11:07-11:13 | 大会发言 |
纳米塑料暴露加重儿童肾积水相关肾损伤及纤维化的肾类器官微流控芯片研究 |
|
||||
| 11:13-11:16 | 大会发言 |
APOE基因变异致脂蛋白肾小球病的家系报道 |
|
||||
| 11:16-11:19 | 大会发言 |
Periconceptional and perinatal risk factors associated with congenital anomalies of the kidney and urinary tract in Chinese children: a population-based study in Qidong, China |
|
||||
| 11:19-11:22 | 大会发言 |
基于尿液蛋白质组的危重症患儿急性肾损伤相关候选标志物筛选与临床验证 |
|
||||
| 11:22-11:25 | 大会发言 |
婴幼儿持续性低尿酸血症的早期识别与遗传诊断价值:SLC2A9复合杂合变异导致RHUC2一例 |
|
||||
| 11:25-11:28 | 大会发言 |
非典型溶血尿毒综合征CFHR基因拷贝数变异及剪接位点突变的致病性研究 |
|
||||
| 11:28-11:31 | 大会发言 |
COL4A3或COL4A4基因杂合致病性变异个体的表型分析 |
|
||||
| 11:31-11:34 | 大会发言 |
一种用于 X 连锁 Alport 综合征诊断标志物与分型的MXene@AuNWs 平台 |
|
||||
| 11:34-11:37 | 大会发言 |
Clinical Genetics in 8273 Pediatric Patients with Kidney Disease in China: Insights from the CCGKDD Database |
|
||||
| 11:37-11:40 | 大会发言 |
免疫双刃剑下的肠道危机:一例肾病患儿脓血便的深度解析 |
|
||||
| 11:40-11:43 | 大会发言 |
儿童IgA血管炎肾炎临床—病理高风险表型不一致性及早期治疗反应:174例单中心回顾性分析 |
|
||||
| 11:43-11:46 | 大会发言 |
320例横纹肌溶解症患儿单中心回顾性研究分析 |
|
||||
| 11:46-11:49 | 大会发言 |
Efficacy and safety of Iptacopan in the treatment of pediatric patients with C3 glomerulopathy |
|
||||
| 11:49-11:52 | 大会发言 |
泰它西普治疗儿童难治性IgA血管炎肾炎的临床疗效及安全性观察 |
|
||||
| 11:52-11:55 | 大会发言 |
贝利尤单抗治疗儿童系统性红斑狼疮的临床疗效研究 |
|
||||
| 11:55-11:58 | 大会发言 |
奥妥珠单抗治疗难治性肾病综合征的31例临床疗效评价 |
|
||||
| 11:58-12:10 |
集体答疑、讨论 |
||||||
| 13:30-13:55 | 专题报告 |
建立可持续的合作研究平台的探索 |
|
||||
| 13:55-14:20 | 专题报告 |
急性肾损伤垂直大模型的开发与应用 |
|
||||
| 14:20-14:45 | 专题报告 |
儿童肾移植远期并发症的长期管理 |
|
||||
| 14:45-15:10 | 专题报告 |
AI背景下的医学教育与人才成长 |
|
||||
| 15:10-15:20 |
集体答疑、讨论 |
||||||
| 15:30-15:40 | 大会发言 |
CPT1A表达下调介导近端肾小管上皮细胞脂质沉积、线粒体损伤及pEMT参与肥胖相关性肾病的作用机制 |
|
||||
| 15:40-15:50 | 大会发言 |
防己茯苓汤经NRF2-ARE通路抑制铁死亡改善急性肾损伤的作用机制及物质基础研究 |
|
||||
| 15:50-16:00 | 大会发言 |
通过单细胞测序揭示在AKI中肾小管细胞群增加Slc7a1表达促进精氨酸转运分子机制 |
|
||||
| 16:00-16:10 | 大会发言 |
NF2 Inhibits CMPK2-Driven NLRP3 Inflammasome Activation to Alleviate Podocyte Injury in FSGS |
|
||||
| 16:10-16:20 | 大会发言 |
M4蛋白诱导新型IgAN小鼠模型的构建及肾脏表型分析 |
|
||||
| 16:20-16:35 |
集体答疑、讨论 |
||||||
| 16:35-16:45 | 大会发言 |
泰它西普改善小鼠IgAN模型肾损伤的机制研究 |
|
||||
| 16:45-16:55 | 大会发言 |
Automated chemiluminescence immunoassay for the detection of antinephrin autoantibodies |
|
||||
| 16:55-17:05 | 大会发言 |
基于区域医疗数据的儿童 系统性红斑狼疮的临床特征、 流行病学和诊疗模式研究 |
|
||||
| 17:05-17:15 | 大会发言 |
线粒体-内质网互作调控内质网自噬介导足细胞损伤的分子机制及干预研究 |
|
||||
| 17:15-17:25 | 大会发言 |
孕母高尿酸血症致子代肾单位发育障碍及其机制的初步研究 |
|
||||
| 17:25-17:35 | 大会发言 |
克拉夫定靶向Ncapd3缓解急性肾损伤向慢性肾脏病进展的作用研究 |
|
||||
| 17:35-17:50 |
集体答疑、讨论 |
||||||